Related Experiment Video
Updated: May 27, 2025
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
10.6K
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study
Jannis Müller1,2,3, Sifat Sharmin1,2, Johannes Lorscheider3
1CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, 3000, Australia.
CNS Drugs
|February 14, 2025
Summary
Switching to lower-efficacy multiple sclerosis (MS) therapies may increase relapse risk. Treatment de-escalation in relapsing-remitting MS (RRMS) should be individualized, not universal.
Area of Science:
- Neurology
- Immunology
- Clinical Therapeutics
Background:
- High-efficacy therapies for relapsing-remitting multiple sclerosis (RRMS) carry risks of side effects, reduced adherence, and increased costs.
- Treatment de-escalation, switching to lower-efficacy therapies, is considered but lacks robust evidence.
- This study aimed to compare clinical outcomes of de-escalation versus continued therapy in RRMS patients.
Purpose of the Study:
- To evaluate the clinical outcomes of treatment de-escalation compared to continuing high-efficacy disease-modifying therapy in patients with RRMS.
- To determine if de-escalation strategies impact relapse rates and disability worsening.
Main Methods:
- Retrospective analysis of a large, international, observational cohort of 87,239 patients with MS.
- Propensity score matching was used to compare 876 patients who de-escalated therapy with matched controls who continued therapy.
- Outcomes assessed included relapses and 6-month confirmed disability worsening using proportional and cumulative hazard models.
Main Results:
- Patients who de-escalated therapy showed a significantly increased hazard of future relapses (HR 2.36, p < 0.001) and recurrent relapses (HR 2.43, p < 0.001).
- This increased relapse risk was consistent across various patient subgroups, including age, sex, disability, and disease duration.
- No specific patient or disease characteristics were identified to clearly guide the safety of de-escalation.
Conclusions:
- Treatment de-escalation in RRMS is associated with a higher risk of relapses.
- De-escalation is not recommended as a universal strategy for RRMS management.
- Individualized patient assessment is crucial when considering treatment de-escalation due to uncertain safety and efficacy.
Related Concept Videos
01:28Drug Therapy
35
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
35
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
01:26Psychosis: Goals of Pharmacotherapy
102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102